Abstract
Introduction
The elderly are at high risk of severe seasonal influenza and influenza-related death. Annual vaccination can effectively prevent influenza and its complications, and is recommended in the elderly. In the present study, surveys were undertaken in France and Germany to determine whether INTANZA® (sanofi pasteur, Val-de-Reuil, France), the first intradermal influenza vaccine, administered using an innovative microneedle injection system, might influence physicians’ likelihood of recommending influenza vaccination or the likelihood that the general public would seek influenza vaccination.
Methods
Physicians (France: n=260; Germany: n=223) and members of the general public aged ≥50 years (France: n=1706; Germany: n=1072) completed online surveys. Details of the INTANZA delivery system, and a “product profile” based on the properties of INTANZA, were presented.
Results
Most physicians and the general public found INTANZA and its microneedle injection system appealing. The main benefit of INTANZA, as perceived by physicians and the public, was the small needle size. Physicians also found the high immunogenicity compared with conventional intramuscular (IM) vaccines attractive. The majority of physicians believed that INTANZA would strongly help them to recommend vaccination to their unvaccinated patients (66% to 91%, depending upon patient characteristics); most (61% to 78%) would prefer to prescribe INTANZA rather than an IM vaccine. More than two-thirds of the unvaccinated general public would prefer INTANZA over IM vaccines, and the option of vaccination with INTANZA would encourage a large proportion of them to get vaccinated (60% to 74%), if it was recommended and they were given the choice. Physicians (≥82%) agreed that INTANZA may help increase vaccination coverage rates.
Conclusion
The results of these surveys indicate that the availability of INTANZA may encourage physicians to recommend influenza vaccination, and members of the general public to get vaccinated. INTANZA may help to improve seasonal influenza vaccination coverage rates.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
World Health Organization. Influenza vaccines. WHO Position Paper. Wkly Epidemiol Rec. 2005;80:279–287.
European Centre for Disease Prevention and Control (ECDC). Seasonal influenza and vaccination — the facts. Available at: http://ecdc.europa.eu/en/healthtopics/Documents/0712_seasonal_human_influenza_vaccination.pdf. Accessed March 21, 2011.
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc. 2003;289:179–186.
World Health Assembly. Fifty-sixth World Health Assembly; Resolution WHA56.19. WHO, Geneva, 2003. Available at: http://www.evm-vaccines.org/pdfs/wha_resolution_ipd.pdf. Accessed May 4, 2011.
European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination (2009/1019/EU). Off J Eur Union. 2009;348:71–72. Available at: http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF. Accessed March 21, 2011.
Samson SI, Mégard Y. Overview of vaccination policies for the elderly in Western European countries. Aging Clin Exp Res. 2009;21:210–215.
Mereckiene J, Cotter S, D’Ancona F et al. VENICE project gatekeepers group. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Euro Surveill. 2010;15:pii:19700.
Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: randomized, controlled, phase III trial. Hum Vaccin. 2010;6:346–354.
Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.
Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26:3197–3208.
Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008;7:1201–1214.
Atmar RL, Patel SM, Keitel WA. Intanza®: a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010;9:1399–1409.
Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21:1769–1775.
INTANZA® 9 and 15 (influenza vaccine injection) product information. France: sanofi pasteur; 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000957/WC500033852.pdf. Accessed March 21, 2011.
Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal vaccination: patient-reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6:336–345.
Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med. 2008;121:S28–S35.
Blank PR, Schwenkglenks M, Szucs TD. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection. 2009;37:390–400.
Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health. 2008;8:272.
Aballéa S, Chancellor J, Martin M, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health. 2007;10:98–116.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at springerlink.com.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Arnou, R., Frank, M., Hagel, T. et al. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Therapy 28, 555–565 (2011). https://doi.org/10.1007/s12325-011-0035-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0035-z